Need for Speed: How Panalgo + Atropos Health Powers Faster Insights for Life Sciences

In June, Panalgo teamed up with Atropos Health, the pioneer in translating real-world clinical data into high-quality personalized real-world evidence for care. The partnership brings together 35 years of evidence generation, technology, and data experience, redefining speed to insight for the industry. In the first of a series of planned initiatives, Panalgo Instant Health Data (IHD) customers will gain access to Atropos Health’s comprehensive suite of evidence-generation tools.  

What does this mean for life sciences organizations working with Panalgo? We spoke with Panalgo’s General Manager Kevin D’Ambrosia to find out how the partnership helps life sciences organizations get better speed to insights and harness the power of GenAI.  

Q: Why did Panalgo engage in the partnership with Atropos Health and how does it bring more value to clients?  

A: Panalgo and Atropos have teamed up to provide a full-service model with the latest AI technologies and more optionality. GenAI is a much-discussed topic in the marketplace right now, and being aligned with Atropos allows us to get into the GenAI game. Atropos’ technology and services complement our trusted research environment of IHD, which streamlines the analytics process by removing complex programming from the equation, allowing you to focus on what matters most: turning data into insights.

The partnership gives clients a full-service model under one roof to empower both your technical and non-technical business teams with the latest AI technologies, with enterprise-wide applicability serving into R&D, clinical, commercial and HEOR teams to democratize data exploration with fast and accurate analysis. Plus, you can layer in the industry’s best technical, scientific, and business full-time equivalent (FTE) talent on top of the technology and tool.

Panalgo clients will benefit from the integration of Panalgo’s trusted IHD environment with GENEVA OS™ (Generative Evidence Acceleration Operating System) and the ChatRWD™ (real-world data) application, a generative AI application incorporating direct chat-to-database capability. This will help healthcare and life science leaders advance and accelerate evidence generation. With the new offering, non-technical users can generate publication-grade observational research studies, leveraging deidentified patient-level RWD from the Atropos Evidence Network in a matter of minutes. It saves organizations time, money, and staffing resources.    

Atropos’ technology complements the power of IHD and allows for speed to insights for those in your organization who don’t have a data science background. Teaming up with Atropos makes more rapid service-level agreement (SLA) turnarounds possible.   

Q: Let’s dive deeper into those improved SLA turnaround times. How does this partnership help life sciences organizations get insights faster?  

The partnership helps you get answers to your research questions faster through the Green Button Service, where you can submit a query—from a simple question or detailed protocol—and receive a full RWE deliverable in less than 48 hours created and reviewed by clinicians, epidemiologists and expert data scientists. 

It also includes ChatRWD, an AI-driven chat-based user experience for RWE that generates responses in less than three minutes. Atropos’s foundational technology allows for user experiences that convert data to evidence. It really provides speed to answers that’s unmatched compared to our competitors.  

Q: Right, as you mentioned, the Panalgo + Atropos partnership provides a full-service model with the latest AI technologies and more optionality. Can you explain what need this fills in the market, and how this works?  

A: It helps life sciences organizations stay on top of the market curve by empowering your team with AI powered capabilities. We often hear that clients can’t get their questions answered or studies done because data scientists – those specialists needed to answer those research questions – are hard to come by. With Panalgo’s IHD platform, anyone can use it – even non-technical users. And now with the addition of Atropos, you have the option of using AI to answer a research question and getting the answer much faster. We’re letting AI act as a helpful assistant to the researcher to get the answers you need faster.  

 Q: What do we bring to the table through this partnership that’s differentiated from our competitors?  

A: The advantage we have over our competitors include the 48-hour SLAs with GenAI capabilities, a decade of publishing expertise, and 300 million patients on demand. Plus, our data is agnostic and federated, with thousands of standardized concepts and customizable healthcare algorithms, with enterprise-level applicability for R&D, clinical, commercial and HEOR teams,  

Together, Panalgo and Atropos unlock features and technology that puts us at a unique advantage over the competition. Clients can build a tailored package that suits their needs, in one place, from light-touch requests to full-service support.  

This partnership is another example of how Panalgo is your partner on the analytics journey, and we’re excited about the possibilities.

 

Ready to learn how Panalgo + Atropos can help you harness the power of GenAI to get insights faster? Contact us.